Biogen Inc. (FRA:IDP)

Market Cap	16.92B
Revenue (ttm)	8.51B
Net Income (ttm)	1.30B
Shares Out	n/a
EPS (ttm)	8.90
PE Ratio	12.98
Forward PE	8.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36
Average Volume	189
Open	113.45
Previous Close	109.85
Day's Range	110.95 - 113.45
52-Week Range	99.00 - 186.85
Beta	n/a
RSI	58.29
Earnings Date	Jul 31, 2025

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IDP

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD